10:07 Quality of Life Improvements for Patients Using GLP-1s Konstantinos (Dino) Spaniolas, MD Now, as patients use these medications, have you seen improvements in their quality of life that maybe are not reflected on their scale
Extreme and rapid weight loss may be a trigger for this condition
Provincial formulary inclusion affects pricing significantly
That said, the CMS will begin a short-term Medicare pilot in July 2026 that lets eligible beneficiaries access GLP-1 weight-loss drugs for $50 per month, followed by a voluntary Medicare Part D coverage model in 2027
We thank WormBase, funded by the National Human Genome Research Institute
Saxenda, are approved for use in New Zealand as adjunctive treatments for weight loss (not funded)